Mahon and colleagues [20] have demonstrated that S100A4 knockdown sensitizes pancreatic cancer cells to gemcitabine treatment, in addition to activating caspases and PARP, resulting in increased apoptosis and cell cycle arrest. The gene discussed is S100A4; the disease is familial pancreatic carcinoma.